Atropine Sulfate Injection is now available in an 8mg per 20mL presentation, the first such multiple-dose vial approved by the Food and Drug Administration. The manufacturer, Fresenius Kabi, today made the announcement of its immediate availability.

Atropine is a muscarinic antagonist indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia.

Related Articles

Atropine Sulfate Injection 8mg per 20mL (0.4mg per mL) is a non-pyrogenic, isotonic, clear solution and is supplied in a multiple-dose glass vial. 

For more information visit Fresenius-Kabi.us.